/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | ADMAADMA BIOLOGICS, INC. |
|---|---|
| Last close | $10.68 |
| Change % | -2.47% |
| Market cap | $2.4B |
| P/E | 17.8 |
| Revenue | $510M |
| Rev growth (YoY) | 19.6% |
| Net income | $147M |
| Net margin | 28.8% |
| EPS (diluted) | $0.60 |
| Piotroski F-ScoreUNVALIDATED | 6 |
| Altman Z-ScoreUNVALIDATED | 12.00 |
| Beneish M-ScoreUNVALIDATED | -0.18 |
| Next earnings | 10-30 → 11-09 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Green = best in the row among the compared names. Educational only — not investment advice.